Please wait...

Quick Stats

Offers Claimed:


Downloaded Today:


Vytorin Prescription
view details
Generic Name: ezetimibe and simvastatin (ez ET i mibe and SIM va stat in)
Brand Names: Vytorin
Vytorin (ezetimibe and simvastatin) lowers bad cholesterol in the blood, and raises good cholesterol. Including Vytorin side effects, interactions and indications. Average Savings for ezetimibe/simvastatin (generic): 48.29%
Generic Name: ezetimibe and simvastatin (ez ET i mibe and SIM va stat in)
Brand Names: Vytorin
Vytorin (ezetimibe and simvastatin) lowers bad cholesterol in the blood, and raises good cholesterol. Including Vytorin side effects, interactions and indications. Average Savings for ezetimibe/simvastatin (generic): 48.29%
  • Select Your Prescription Settings
  • X
30 tablets of Vytorin 40 mg
  • Select Your Prescription Settings
  • X

Quick Stats

Offers Claimed: 30

Downloaded Today: 112

Set your location
for drug prices near you

Vytorin Coupons & Prices

Set your location
for drug prices near you

Enter your ZIP Code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Vytorin Drug Information:

Vytorin contains a combination of Ezetimibe and Simvastatin. Ezetimibe reduces the amount of cholesterol absorbed by the body. Simvastatin belongs to a group of drugs called HMG CoA reductase inhibitors, or "statins." Vytorin is used to lower blood levels of "bad" cholesterol (low-density lipoprotein, or LDL) and triglycerides, to increase levels of "good" cholesterol (high-density lipoprotein, or HDL), and to lower triglycerides (a type of fat in the blood). Vytorin is used together with a low-fat diet and other treatments to lower total cholesterol in adults and children who are at least 10 years old. It is not known whether this medicine reduces your risk of heart disease. Learn more

Vytorin Side Effects

Note: This document contains side effect information about ezetimibe / simvastatin. Some of the dosage forms listed on this page may not apply to the brand name Vytorin.

For the Consumer

Applies to ezetimibe / simvastatin: oral tablet

Along with its needed effects, ezetimibe/simvastatin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ezetimibe / simvastatin:

Incidence not known

  • Abdominal or stomach fullness
  • bloating
  • chills
  • constipation
  • darkened urine
  • fast heartbeat
  • fever
  • hives
  • hoarseness
  • indigestion
  • itching
  • joint pain
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • loss of appetite
  • nausea
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • rash
  • redness of the skin
  • shortness of breath
  • stiffness
  • swelling of the eyelids, face, lips, hands, or feet
  • tightness in the chest
  • trouble breathing or swallowing
  • vomiting
  • yellow eyes or skin

Some side effects of ezetimibe / simvastatin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Body aches or pain
  • cough
  • diarrhea
  • difficulty with breathing
  • difficulty with moving
  • ear congestion
  • general feeling of discomfort or illness
  • headache
  • loss of voice
  • muscle aches and pains or cramping
  • muscle stiffness
  • nasal congestion
  • pain in the arms or legs
  • runny nose
  • shivering
  • sneezing
  • sore throat
  • sweating
  • swollen joints
  • trouble sleeping
  • unusual tiredness or weakness

For Healthcare Professionals

Applies to ezetimibe / simvastatin: oral tablet


The more commonly reported adverse effects have included headache, increased ALT, myalgia, upper respiratory tract infection, and diarrhea.



Common (1% to 10%): Diarrhea


Common (1% to 10%): Diarrhea, abdominal pain, nausea

Postmarketing reports: Pancreatitis


Common (1% to 10%): Constipation, nausea, flatulence, diarrhea, dyspepsia, abdominal pain, pancreatitis, anorexia, vomiting, gastritis

Very rare (less than 0.01%): Protein losing enteropathy



Common (1% to 10%): Myalgia, extremity pain

Very rare (less than 0.01%): Tendon rupture (one case)

Frequency not reported: Back pain

Postmarketing reports: Muscle cramps


Common (1% to 10%): Back pain, arthralgia

Postmarketing reports: Myalgia, elevated creatine phosphokinase, rare reports of myopathy/rhabdomyolysis


Uncommon (0.1% to 1%): Myopathy, rhabdomyolysis

Frequency not reported: Elevations in creatine kinase, dermatomyositis, arthralgia, myalgia

Simvastatin has been associated with rare cases of severe myopathy and rhabdomyolysis. This is accompanied by elevations in creatine kinase, myoglobinuria, and proteinuria, as well as renal failure. Experience with HMG-CoA reductase inhibitors indicates that concomitant use with gemfibrozil, niacin, cyclosporine, or erythromycin may increase the incidence and the severity of musculoskeletal side effects.

A case of spontaneous biceps tendon rupture developed in a patient after 4 months of treatment with ezetimibe-simvastatin. Upon rechallenge 2 months later, the patient developed pain in the contralateral arm overlying the biceps tendon. Following discontinuation of ezetimibe-simvastatin, pain resolved 2 weeks later. Inhibition of matrix metalloproteinases has been suggested as the contributing factor in the development of tendon rupture.



Frequency not reported: Myoglobinuria, acute renal failure secondary to rhabdomyolysis


Persistent elevations in liver function tests three times normal values are reported in up to 1.5% of patients on simvastatin in clinical trials. In one study, this led to the discontinuation of simvastatin in 0.6% of patients. In other patients, elevations in liver function tests were transient and returned to normal with continued simvastatin therapy.


Common (1% to 10%): Increased ALT

Frequency not reported: Increased AST


Postmarketing reports: Elevations in liver transaminases, hepatitis, cholelithiasis, cholecystitis


Common (1% to 10%): Elevations in liver function tests

Frequency not reported: Hepatitis (including chronic active hepatitis), cholestatic jaundice, fatty changes in the liver, cirrhosis, fulminant hepatic necrosis

Postmarketing reports: Hepatic failure, jaundice



Frequency not reported: Eczematous, pruritic rash, toxic epidermal necrolysis, photosensitivity, purpura, erythema multiforme, photosensitivity, purpura, alopecia

Postmarketing reports: A variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails)



Frequency not reported: Influenza


Common (1% to 10%): Viral infection


Very rare (less than 0.01%): Lupus-like syndrome

Frequency not reported: Positive ANA, ESR increase, polymyalgia rheumatica, vasculitis

Statin use:

Rare (0.01% to 0.1%): Immune-mediated necrotizing myopathy (IMNM)



Common (1% to 10%): Upper respiratory tract infection

Frequency not reported: Interstitial lung disease causing breathing problems including persistent cough and/or shortness of breath or fever


Common (1% to 10%): Coughing

Frequency not reported: Sinusitis


Frequency not reported: Sinusitis, pharyngitis



Common (1% to 10%): Angina

Frequency not reported: Atrial fibrillation, edema



Frequency not reported: Gynecomastia, thyroid function abnormalities



Frequency not reported: Erectile dysfunction, impotence, urinary tract infections



Postmarketing reports: Epistaxis (one report), anemia


Postmarketing reports: Thrombocytopenia


Frequency not reported: Hemolytic anemia, thrombocytopenia, leukopenia (possibly manifestations of a hypersensitivity reaction)

A 65-year-old male with hereditary hemorrhagic telangiectasia (HHT) who had a history of minimal epistaxis began to experience profuse epistaxis 8 to 10 weeks after starting ezetimibe-simvastatin, The patient had been treated with simvastatin 20 mg alone for 9 years without any adverse effects. Two months after starting combination therapy with ezetimibe-simvastatin he noticed epistaxis that increased from a few drops every other day to profuse bleeding for 20 to 30 minutes daily. The patient reported initiation of ezetimibe-simvastatin as the only change in his treatment regimen in the past year. When he stopped ezetimibe-simvastatin, his epistaxis decreased. After six weeks without ezetimibe-simvastatin, he had only one moderate nose bleed. Four months later, the patient's hemoglobin was stable. He then started simvastatin 40 mg monotherapy. The profound epistaxis returned and the patient discontinued the medication. It remains unclear whether the patient's accelerated epistaxis was due to the combination therapy or the double dosage of simvastatin.


Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported. In addition, an apparent hypersensitivity syndrome has been reported rarely that has included one or more of the following features: anaphylaxis, angioedema, lupus erythematous-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome.


Postmarketing reports: Angioedema, anaphylaxis, rash, urticaria


Rare (less than 0.1%): Erythema multiforme, Stevens-Johnson syndrome, anaphylaxis, angioedema, urticaria, fever, chills, flushing, malaise, dyspnea

Postmarketing reports: Hypersensitivity reactions

Nervous system

A case of memory loss possibly related to simvastatin use has been reported. The patient developed gradual memory loss following 12 months of simvastatin therapy. He was switched to pravastatin, and within a month his memory was intact. Rechallenge with simvastatin was not performed.

There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These reports have been generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).


Common (1% to 10%): Headache

Frequency not reported: Confusion, fatigue


Postmarketing reports: Dizziness, paraesthesia


Frequency not reported: Cranial nerve dysfunction, tremor, vertigo, memory loss, paraesthesias, peripheral neuropathy, peripheral nerve palsy


Postmarketing reports: Cognitive impairment



Frequency not reported: Progression of cataracts, ophthalmoplegia



Frequency not reported: Liver, thyroid, and lung adenomas and carcinomas



Frequency not reported: Depression, suicidal thoughts, delusions, paranoia, agitation, decreased libido, anxiety, insomnia



Frequency not reported: Increases in HbA1c and fasting serum glucose levels



Frequency not reported: Fatigue, asthenia

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/3/2022.

Source: Drugs.com Vytorin (www.drugs.com/vytorin.html).